A 2011. évi B19 humán parvovírus-fertozésekrol szerzett tapasztalatok

Translated title of the contribution: Observations on human parvovirus B19 infection diagnosed in 2011

Ilona Mihály, András Trethon, Z. Arányi, Adrienne Lukács, Tímea Kolozsi, Gyula Prinz, Anikó Marosi, Nóra Lovas, Ilona Sarolta Dobner, Géza Prinz, Z. Szalai, Tamás Pék

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Introduction: The incidence of human parvovirus B19 infection is unknown. Aim: A retrospective analysis of clinical and laboratory findings was carried out in patients diagnosed with human parvovirus B19 infection in 2011 in a virologic laboratory of a single centre in Hungary. Methods: Clinical and laboratory data of patients with proven human parvovirus B19 infection were analysed using in- and out-patient files. Results: In 2011, 72 patients proved to have human parvovirus B19 infection with the use of enzyme immunoassay. The clinical diagnoses of these patients were as follows: human parvovirus B19 infection (30.6%), transient aplastic crisis (16.7%), arthritis (8.3%) and acute hepatitis (4.1%). Symptoms of each of the four phases of the infection occurred in various combinations with the exception of the monophase of cheek exanthema. This occurred without the presence of other symptoms in some cases. Leading symptoms and signs were exanthema (in 74.6% of cases), haematological disorders (in 69% of cases), fever (in 54.9% of cases) and arthritis (in 33.8% of cases). Several atypical dermatological symptoms were also observed. Acute arthritis without exanthema was noted in 8 patients. Of the 72 patients with proven human parvovirus B19 infection there were 7 pregnant women, and one of them had hydrops foetalis resulting spontaneous abortion. In 16 patients (22.5%) human parvovirus B19 IgG was undetectable despite an optimal time for testing. Conclusion: The observations of this study may contribute to a better recognition of clinical symptoms of human parvovirus B19 infection.

Original languageHungarian
Pages (from-to)1948-1957
Number of pages10
JournalOrvosi Hetilap
Volume153
Issue number49
DOIs
Publication statusPublished - Dec 1 2012

Fingerprint

Human Parvovirus B19
Parvoviridae Infections
Exanthema
Arthritis
Hungary
Cheek
Spontaneous Abortion
Immunoenzyme Techniques
Hepatitis
Signs and Symptoms
Pregnant Women
Edema
Fever
Outpatients
Immunoglobulin G

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mihály, I., Trethon, A., Arányi, Z., Lukács, A., Kolozsi, T., Prinz, G., ... Pék, T. (2012). A 2011. évi B19 humán parvovírus-fertozésekrol szerzett tapasztalatok. Orvosi Hetilap, 153(49), 1948-1957. https://doi.org/10.1556/OH.2012.29447

A 2011. évi B19 humán parvovírus-fertozésekrol szerzett tapasztalatok. / Mihály, Ilona; Trethon, András; Arányi, Z.; Lukács, Adrienne; Kolozsi, Tímea; Prinz, Gyula; Marosi, Anikó; Lovas, Nóra; Dobner, Ilona Sarolta; Prinz, Géza; Szalai, Z.; Pék, Tamás.

In: Orvosi Hetilap, Vol. 153, No. 49, 01.12.2012, p. 1948-1957.

Research output: Contribution to journalArticle

Mihály, I, Trethon, A, Arányi, Z, Lukács, A, Kolozsi, T, Prinz, G, Marosi, A, Lovas, N, Dobner, IS, Prinz, G, Szalai, Z & Pék, T 2012, 'A 2011. évi B19 humán parvovírus-fertozésekrol szerzett tapasztalatok', Orvosi Hetilap, vol. 153, no. 49, pp. 1948-1957. https://doi.org/10.1556/OH.2012.29447
Mihály I, Trethon A, Arányi Z, Lukács A, Kolozsi T, Prinz G et al. A 2011. évi B19 humán parvovírus-fertozésekrol szerzett tapasztalatok. Orvosi Hetilap. 2012 Dec 1;153(49):1948-1957. https://doi.org/10.1556/OH.2012.29447
Mihály, Ilona ; Trethon, András ; Arányi, Z. ; Lukács, Adrienne ; Kolozsi, Tímea ; Prinz, Gyula ; Marosi, Anikó ; Lovas, Nóra ; Dobner, Ilona Sarolta ; Prinz, Géza ; Szalai, Z. ; Pék, Tamás. / A 2011. évi B19 humán parvovírus-fertozésekrol szerzett tapasztalatok. In: Orvosi Hetilap. 2012 ; Vol. 153, No. 49. pp. 1948-1957.
@article{f64313c3b0724a28ae2cbc82b64b3f20,
title = "A 2011. {\'e}vi B19 hum{\'a}n parvov{\'i}rus-fertoz{\'e}sekrol szerzett tapasztalatok",
abstract = "Introduction: The incidence of human parvovirus B19 infection is unknown. Aim: A retrospective analysis of clinical and laboratory findings was carried out in patients diagnosed with human parvovirus B19 infection in 2011 in a virologic laboratory of a single centre in Hungary. Methods: Clinical and laboratory data of patients with proven human parvovirus B19 infection were analysed using in- and out-patient files. Results: In 2011, 72 patients proved to have human parvovirus B19 infection with the use of enzyme immunoassay. The clinical diagnoses of these patients were as follows: human parvovirus B19 infection (30.6{\%}), transient aplastic crisis (16.7{\%}), arthritis (8.3{\%}) and acute hepatitis (4.1{\%}). Symptoms of each of the four phases of the infection occurred in various combinations with the exception of the monophase of cheek exanthema. This occurred without the presence of other symptoms in some cases. Leading symptoms and signs were exanthema (in 74.6{\%} of cases), haematological disorders (in 69{\%} of cases), fever (in 54.9{\%} of cases) and arthritis (in 33.8{\%} of cases). Several atypical dermatological symptoms were also observed. Acute arthritis without exanthema was noted in 8 patients. Of the 72 patients with proven human parvovirus B19 infection there were 7 pregnant women, and one of them had hydrops foetalis resulting spontaneous abortion. In 16 patients (22.5{\%}) human parvovirus B19 IgG was undetectable despite an optimal time for testing. Conclusion: The observations of this study may contribute to a better recognition of clinical symptoms of human parvovirus B19 infection.",
keywords = "Arthritis, Exanthematous infections, Gestational parvovirus B19 infection, Parvovirus B19 infection, Transient aplastic crisis",
author = "Ilona Mih{\'a}ly and Andr{\'a}s Trethon and Z. Ar{\'a}nyi and Adrienne Luk{\'a}cs and T{\'i}mea Kolozsi and Gyula Prinz and Anik{\'o} Marosi and N{\'o}ra Lovas and Dobner, {Ilona Sarolta} and G{\'e}za Prinz and Z. Szalai and Tam{\'a}s P{\'e}k",
year = "2012",
month = "12",
day = "1",
doi = "10.1556/OH.2012.29447",
language = "Hungarian",
volume = "153",
pages = "1948--1957",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "49",

}

TY - JOUR

T1 - A 2011. évi B19 humán parvovírus-fertozésekrol szerzett tapasztalatok

AU - Mihály, Ilona

AU - Trethon, András

AU - Arányi, Z.

AU - Lukács, Adrienne

AU - Kolozsi, Tímea

AU - Prinz, Gyula

AU - Marosi, Anikó

AU - Lovas, Nóra

AU - Dobner, Ilona Sarolta

AU - Prinz, Géza

AU - Szalai, Z.

AU - Pék, Tamás

PY - 2012/12/1

Y1 - 2012/12/1

N2 - Introduction: The incidence of human parvovirus B19 infection is unknown. Aim: A retrospective analysis of clinical and laboratory findings was carried out in patients diagnosed with human parvovirus B19 infection in 2011 in a virologic laboratory of a single centre in Hungary. Methods: Clinical and laboratory data of patients with proven human parvovirus B19 infection were analysed using in- and out-patient files. Results: In 2011, 72 patients proved to have human parvovirus B19 infection with the use of enzyme immunoassay. The clinical diagnoses of these patients were as follows: human parvovirus B19 infection (30.6%), transient aplastic crisis (16.7%), arthritis (8.3%) and acute hepatitis (4.1%). Symptoms of each of the four phases of the infection occurred in various combinations with the exception of the monophase of cheek exanthema. This occurred without the presence of other symptoms in some cases. Leading symptoms and signs were exanthema (in 74.6% of cases), haematological disorders (in 69% of cases), fever (in 54.9% of cases) and arthritis (in 33.8% of cases). Several atypical dermatological symptoms were also observed. Acute arthritis without exanthema was noted in 8 patients. Of the 72 patients with proven human parvovirus B19 infection there were 7 pregnant women, and one of them had hydrops foetalis resulting spontaneous abortion. In 16 patients (22.5%) human parvovirus B19 IgG was undetectable despite an optimal time for testing. Conclusion: The observations of this study may contribute to a better recognition of clinical symptoms of human parvovirus B19 infection.

AB - Introduction: The incidence of human parvovirus B19 infection is unknown. Aim: A retrospective analysis of clinical and laboratory findings was carried out in patients diagnosed with human parvovirus B19 infection in 2011 in a virologic laboratory of a single centre in Hungary. Methods: Clinical and laboratory data of patients with proven human parvovirus B19 infection were analysed using in- and out-patient files. Results: In 2011, 72 patients proved to have human parvovirus B19 infection with the use of enzyme immunoassay. The clinical diagnoses of these patients were as follows: human parvovirus B19 infection (30.6%), transient aplastic crisis (16.7%), arthritis (8.3%) and acute hepatitis (4.1%). Symptoms of each of the four phases of the infection occurred in various combinations with the exception of the monophase of cheek exanthema. This occurred without the presence of other symptoms in some cases. Leading symptoms and signs were exanthema (in 74.6% of cases), haematological disorders (in 69% of cases), fever (in 54.9% of cases) and arthritis (in 33.8% of cases). Several atypical dermatological symptoms were also observed. Acute arthritis without exanthema was noted in 8 patients. Of the 72 patients with proven human parvovirus B19 infection there were 7 pregnant women, and one of them had hydrops foetalis resulting spontaneous abortion. In 16 patients (22.5%) human parvovirus B19 IgG was undetectable despite an optimal time for testing. Conclusion: The observations of this study may contribute to a better recognition of clinical symptoms of human parvovirus B19 infection.

KW - Arthritis

KW - Exanthematous infections

KW - Gestational parvovirus B19 infection

KW - Parvovirus B19 infection

KW - Transient aplastic crisis

UR - http://www.scopus.com/inward/record.url?scp=84870620900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870620900&partnerID=8YFLogxK

U2 - 10.1556/OH.2012.29447

DO - 10.1556/OH.2012.29447

M3 - Article

C2 - 23204301

AN - SCOPUS:84870620900

VL - 153

SP - 1948

EP - 1957

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 49

ER -